{"slideshow_credits": null, "snippet": "The British drug maker has agreed to pay $105 million to settle allegations by 44 states and the District of Columbia that it promoted its medicines for unapproved uses.", "abstract": "GlaxoSmithKline has agred to pay $105 million to settle allegations by 44 states and the District of Columbia that it promoted its medicines for unapproved uses.", "section_name": "Business Day", "print_page": "2", "document_type": "article", "byline": {"person": [], "organization": "REUTERS", "original": "By REUTERS", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/06/05/business/glaxosmithkline-settles-on-marketing-allegations.html", "lead_paragraph": "The British drug maker has agreed to pay $105 million to settle allegations by 44 states and the District of Columbia that it promoted its medicines for unapproved uses.", "headline": {"main": "Glaxosmithkline Settles on Marketing Allegations", "print_headline": "Glaxosmithkline Settles on Marketing Allegations", "content_kicker": "Business Briefing"}, "_id": "538fb8d338f0d86de266c004", "word_count": "115", "multimedia": [], "pub_date": "2014-06-05T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"value": "States (US)", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "GlaxoSmithKline PLC", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Fines (Penalties)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Suits and Litigation (Civil)", "name": "subject", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": null, "type_of_material": "Brief"}